Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

Major granted approvals 2022 US EU China Vabysmo (faricimab) RG7716 DME Jan 2022 RG7596 Polivy 1L DLBCL May 2022 RG7446 Tecentriq NSCLC adj March 2022 RG1569 Vabysmo (faricimab) RG7716 WAMD RG7446 Tecentriq NSCLC adj Actemra RG1569 RA SC RG7716 Japan-Chugai Actemra COVID-19 pneumonia Jan 2022 Vabysmo (faricimab) DME Jan 2022 June 2022 April 2022 RG1569 RG7916 Actemra GCA IV Feb 2022 Evrysdi SMA presymptomatic pediatric <2mo May 2022 Lunsumio (mosunetuzumab) March 2022 Vabysmo (faricimab) RG7828 3L+FL RG7716 WAMD June 2022 March 2022 Perjeta + Herceptin RG1273 HER-2+ CRC New Molecular Entity (NME) Additional Indication (AI) Oncology/Hematology Immunology Infectious Diseases Status as of July 21, 2022 Metabolism Neuroscience Ophthalmology Other RG7446 RG6013 RG105 March 2022 Tecentriq NSCLC adj May 2022 Hemlibra acquired Hemophilia A June 2022 Rituxan NMOSD June 2022 79 64 Roche
View entire presentation